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Christian Forster, Jens Schriewer, Stefan John, Kai-Uwe Eckardt and Carsten Willam*Abstract
Introduction: Lung-protective ventilation in patients with ARDS and multiorgan failure, including renal failure, is
often paralleled with a combined respiratory and metabolic acidosis. We assessed the effectiveness of a hollow-fiber
gas exchanger integrated into a conventional renal-replacement circuit on CO2 removal, acidosis, and
hemodynamics.
Methods: In ten ventilated critically ill patients with ARDS and AKI undergoing renal- and respiratory-replacement
therapy, effects of low-flow CO2 removal on respiratory acidosis compensation were tested by using a hollow-fiber
gas exchanger added to the renal-replacement circuit. This was an observational study on safety, CO2-removal
capacity, effects on pH, ventilator settings, and hemodynamics.
Results: CO2 elimination in the low-flow circuit was safe and was well tolerated by all patients. After 4 hours of
treatment, a mean reduction of 17.3 mm Hg (−28.1%) pCO2 was observed, in line with an increase in pH. In
hemodynamically instable patients, low-flow CO2 elimination was paralleled by hemodynamic improvement, with
an average reduction of vasopressors of 65% in five of six catecholamine-dependent patients during the first
24 hours.
Conclusions: Because no further catheters are needed, besides those for renal replacement, the implementation of
a hollow-fiber gas exchanger in a renal circuit could be an attractive therapeutic tool with only a little additional
trauma for patients with mild to moderate ARDS undergoing invasive ventilation with concomitant respiratory
acidosis, as long as no severe oxygenation defects indicate ECMO therapy.
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In modern intensive care medicine, patients with
multiorgan failure frequently need respiratory ventilation
and renal-replacement therapy to bridge organ dysfunc-
tion. Ventilation itself, in particular with the use of high
tidal volumes and high airway pressures, has been shown
to be deleterious for patient outcomes [1,2], and thus
protective ventilation strategies, including lower tidal
volumes, have been implemented into clinical practice
[1,3]. Although these ventilation specifications often lead
to respiratory acidosis, the concept of permissive hyper-
capnia and concomitant acidosis is presently widely* Correspondence: carsten.willam@uk-erlangen.de
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reproduction in any medium, provided the oraccepted, albeit still controversially discussed in the
scientific community. Whereas evidence has been pro-
vided for immunologic, redox, and vasoactive protective
effects, acidosis has also been associated with higher
hemodynamic instability [4-7]. Extracorporeal mem-
brane oxygenation (ECMO) [2,8-10] and pumpless CO2-
removal systems (PECLA) [11,12] are increasingly used
to support lung-protective ventilation strategies and to
improve CO2 removal and respiratory acidosis. Import-
antly, in the recent Xtravent study by Bein et al. [13],
pumpless CO2 removal enabled efficient low-tidal venti-
lation (about 3 ml/kg PBW) without severe acidosis,
which was also associated with more ventilator-free days
for patients having a severe oxygenation deficit (PaO2/
FIO2 <150). However, in all of these therapies, a higherLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and trauma by using special cannulas with big diameters
to the patient is mandatory.
About 35% to 60% of the patients undergoing re-
spiratory therapies in multiorgan failure also need
renal-replacement therapies (RRTs) [14,15]. Because,
in these patients with concomitant renal failure, extra-
corporeal blood circuits have necessarily already been
established for renal-replacement therapy, we won-
dered whether addition of a hollow-fiber gas exchanger
to the low-flow blood circuit could support lung-
protective strategies by improving respiratory acidosis.
Although renal-replacement circuits allow only a blood
flow of 300 to 500 ml/min, partial elimination of CO2
appears to be feasible [16]. Arterial blood with a pCO2
of 40 mm Hg (5.3 kPa) contains approximately 500 ml
CO2/L (pH 7.4). In sheep experiments, Young et al. [17]
achieved 130 to 180 ml CO2 elimination (500 ml/L pCO2
in blood at 40 mm Hg (5.3 kPa) calculated) by using
blood-flow rates of about 500 ml/min, combining a
hollow-fiber gas exchanger and a hemofiltration device.
Livigni et al. [18] also tested effects of low-flow CO2
elimination in sheep by using a veno-venous pump-
driven bypass. They found an average CO2 reduction of
hypercapnic ventilated sheep of 17% to 22%. Batchinsky
et al. [19] were able to achieve normocapnia in hypercap-
nic ventilated pigs by using a veno-venous pump-driven
system (400 to 600 ml/min blood flow), including a gas
exchanger. Altogether, experimental evidence suggests,
therefore, that a significant amount of basal CO2 produc-
tion can be eliminated in low-flow veno-venous systems.
First experiences in critically ill patients applying CO2 re-
moval with low-flow veno-venous systems were gained by
using a specialized device with a hollow-fiber gas exchan-
ger adapted to low blood flows (about 350 ml/min;
“DecapSmart”). First, case reports described successful ap-
plication of this system in single patients [20-23]. Eventu-
ally, a clinical study using the DecapSmart system was
able to demonstrate effects of low-flow CO2 removal in
critically ill patients. Here in 10 patients being ventilated
with a plateau pressure between 28 and 30 cm H2O and
having respiratory acidosis, additional low-flow CO2 re-
moval reduced pCO2 from 73.6 to 50.4 mm Hg and in-
creased pH from 7.20 to 7.32 in 60 to 90 minutes [24].
However, the DecapSmart system still needs a specialized
device and cannulation, which needs vascular access side
to side with cannulas needed for renal-replacement ther-
apy in severe AKI. We thus wondered whether implemen-
tation of a hollow-fiber gas exchanger into the renal
circuit could combine low-flow CO2 removal and renal-
replacement therapy by using one system and blood ac-
cess and tested for ventilatory and hemodynamic effects
in 10 severely ill patients with combined respiratory and
renal failure.Materials and methods
CRRT circuit
We used a CVVHD device (bm11/14; Edwards-Lifescience,
Irvine, CA, USA) with a standard setup and adjustment for
continuous venovenous hemodialysis. A high-flux polysulfone
capillary hemofilter with a membrane surface area of 1.4 m2
(Polyflux 140 H; Gambro, Hechingen, Germany ) was used.
For decarboxylation, a small standard hollow-fiber gas
exchanger (D902 Liliput 2 ECMO; Sorin Group Milan,
Italy) was applied. This gas exchanger has a surface
area of 0.67 m2 and is intended for extracorporeal cir-
cuits with a maximum blood flow of 2,300 ml/min.
According to the manufacturer’s description, the filter is
coated with phosphorylcholine, which should form a
phospholipid-like structure and reduce coagulation. The
gas exchanger was integrated into the continuous
hemodialysis system after the dialysis filter. For the
connection, we used standard tubes with a Luer-lock sys-
tem. The gas exchanger was attached to the hemodialysis
machine with a conventional clamp (Figure 1). Venous
and arterial pressures were monitored continuously. Gas
flow through the gas exchanger was set to 4 L/min (blood
flow, <300 ml/min) or 4 to 6 L/min (blood flow, >300 ml/
min) with a FiO2 of 0.21. Only in cases in which oxygen-
ation by the ventilator was critical, the FiO2 was varied
(0.5 to 1.0 FiO2), in the hope of counteracting systemic
hypoxia. For reasons of simplicity, we called this setting
“lung-assisting renal replacement system” or “LARRS.”
The LARRS system was tested beforehand in “dummy”
experiments, yielding no detectable changes in venous,
arterial, and transmembrane pressures and confirming
the full function of alarms, bubble catcher, and emer-
gency shutter. In particular, flushing the system with air
by artificial occlusion of all three ventilation tubes of the
oxygenator led to prompt emergency standby of the
CVVHD circuit, according to security standards in
renal-replacement therapy devices. Also when the sys-
tem was subsequently applied to patients, the pressure
control of the hemodialysis did not show any differences
in the presence of the gas exchanger in comparison to
conventional renal-replacement therapy.
Blood flow was primarily adjusted to 400 ml/min, but
could be adapted to individual needs and circumstances
(300 to 500 ml/min). A 13.5-French double-lumen cath-
eter was placed into the jugular vein. In two patients, we
used a second 13.5-French double-lumen catheter in the
femoral vein to allow higher blood flows. In this case,
the two lumina of one catheter were linked by a y-
adapter to form a single blood line. This allowed in-
creasing the blood flow about 30% to 40% in these two
patients. The dialysate contained Na, 140 mM; K, 4.0 M;
Ca, 1.5 mM; Mg, 0.5 mM; Cl, 113 mM; HCO3, 35.0 mM;
and D-Glucose, 9.0 g/L. Anticoagulation was performed
with systemic heparin, and doses were prescribed
Figure 1 Scheme of the renal circuit with implementation of a hollow-filter gas exchanger.
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time (ACT), which was measured in bedside assays of
160 to 200 seconds. To prevent cooling of the patient,
we used a tube heating system (Fresenius, Germany),
which was set to 37°C.
Patient inclusion
Patients were treated with the hollow-fiber gas exchanger
in the renal circuit according to the individual decision of
the treating physician, based on the patient’s characte-
ristics and needs. Inclusion criteria were primarily the
need for renal-replacement and mechanical-ventilation
therapy with concomitant hypercapnic respiratory acid-
osis (pH <7.25). The treatment protocol was approved
by the local Ethics Committee of the University of
Erlangen-Nuremberg, Germany. In all cases, written in-
formed consent was obtained from a legal guardian of
the patient before application of the gas-exchange filter
was started.
All patients had a central venous catheter in addition
to the double-lumen catheters used for RRT, a urinary
catheter (unless they were anuric), and an invasive
blood-pressure measurement. Heart rate, blood pressure,
SaO2, and temperature were monitored continuously; di-
uresis was measured hourly, and arterial blood gases
were measured in variable intervals during the whole
stay at the intensive care unit. Norepinephrine infusions
were applied in parallel to fluid administration to main-
tain a mean arterial pressure of 65 mm Hg.
Statistics
Because of the small number of patients, most results
were presented for each case in absolute values or bycalculating differences between baseline and 24 hours
after commencing treatment. Means are expressed as
mean ± SD of the mean.
Results
Patient characteristics
We treated 10 patients with the hollow-filter gas exchan-
ger (LARRS) between November 2009 and January 2011.
All patients were already undergoing CVVHD because
of acute renal failure and oliguria when the CO2 hollow
filter was applied. At inclusion, the arterial pH varied
from 7.07 to 7.24; patient 7 was included to prevent pro-
gressive respiratory failure and exhaustion due to a still-
compensated respiratory acidosis (HCO3, 31 mM; pCO2,
55 mm Hg; pH 7.37). The patients’ baseline characteris-
tics are summarized in Table 1. Eight patients had
community-acquired pneumonia; the other two patients
had acute infectious exacerbation of COPD. Two pa-
tients (1 and 2) fulfilled ARDS criteria, but had contrain-
dications against ECMO therapy. One patient (5) with
severe ARDS was treated briefly for bridging until
ECMO therapy was installed. Although this patient had
preexisting high bicarbonate values (37 mm Hg) because
of long-term adaptation to his COPD, this patient deve-
loped progressive respiratory acidosis (pH 7.34; pCO2,
88 mm Hg) owing to his severe respiratory failure and
increasing difficulties in ventilation support. The mean
APACHE II score was 29.6 (APACHE II, 22 to 35), with
a mean predicted mortality of 72% (40% to 82%).
CO2 elimination in the CRRT circuit
Treatment modalities are summarized in Table 2. Appli-
cation of the hollow-fiber gas-exchanger CVVHD system
Table 1 Baseline patients’ characteristics and outcomes of the 10 patients treated with the hollow-fiber gas-exchange
device included in the renal-replacement circuit




















3 57 F 160 55 17 141 28 13 Pneumonia Weaning
and
recovery
4 67 M 175 80 25 265 32 3 COPD Weaning
and
recovery




Died on multiple organ
failure 12 days later
6 74 M 170 90 31 93 35 1 Pneumonia Weaning
and
recovery
7 73 F 155 88 37 267 32 3 COPD Weaning
and
recovery
8 73 F 148 115 53 130 33 6 Pneumonia Weaning Died 25 days later –
mesenteric ischemia





10 54 M 180 98 30 200 24 1 Pneumonia Weaning
and
recovery
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of the CVVHD device and the renal-replacement filter
was detectable or necessary. Blood-flow rates from
250 ml to 500 ml could be achieved in all patients (mean,









t = 4 h t = 24 h t = 4 h t = 24 h t = 4 h
1 1 250 300 4.0 4.0 100
2 1 330 400 2.0 2.0 200
3 1 400 400 2.0 2.0 0
4 1 400 400 2.0 2.0 0
5 2 300a n.a. 2.0 a n.a. 100 a
6 1 500 450 3.0 3.0 0
7 1 320 250 2.0 2.0 100
8 2 400 450 2.0 1.5 40
9 1 400 500 2.0 2.0 0
10 1 250 250 2.0 2.0 50
Patient 5 was switched to ECMO after 2.5 hours of treatment and was therefore nopressures in the system were not altered. All patients
tolerated the intervention well, and no complications
occurred during the therapy. Mean heparin doses were
815 (t = 0 hours) and 1,116 IU/h (t = 24 hours), resulting











t = 24 h t = 24 h
200 −645 6 1.00 30
0 −705 4 1.00 84
150 605 4 0.50 45
100 1,715 6 0.40 215
n.a. n.a. 6 0.21 2.5
100 1,340 6 0.21 191
150 −3,345 4 0.21 83
100 −2,055 6 0.21 71
0 180 6 0.21 92
0 2,945 4 0.21 134
t applicable at t = 4 hours and t = 24 hours. at = 2.5 hours. n.a., not applicable.
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hours) and 213 seconds (t = 24 hours) in bedside tests (see
Additional file 1: Table S1). Two episodes of clotting were
observed. In one case, the renal filter clotted after 23
hours of use and had to be exchanged. In a second case,
the hollow-fiber gas exchanger clotted, which led to a
rapid decrease of the arterial pH and increase of pCO2 in
the extracorporeal system and activated pressure alarms
of the dialysis machine. In this case, the hollow-fiber gas
exchanger was exchanged immediately, which quickly re-
stored CO2 removal and pH compensation.
Overall, in-device blood gas analysis directly after the
hollow-fiber gas exchanger showed a mean reduction of
extracorporeal pCO2 of 39 mm Hg (63 mm Hg before
gas-exchanger to 24 mm Hg after gas-exchanger filter;
see Additional file 2: Figure S1), resulting in a mean in-
crease of pH of 0.31 (pH 7.28 before filter and 7.59 after
filter, mean blood flow of 377 ml/min). The pO2 in the
extracorporeal system increased from 41 mm Hg (before
filter) to 122 mm Hg (after filter), but no change oc-
curred in the patients’ systemic pO2. (Additional file 2:
Figure S1).
Blood-gas changes during the course of therapy
Implementation of the hollow-fiber gas exchanger re-
duced the average systemic arterial pCO2 by 17.3 mm
Hg or 28.1% in about 4 hours (Table 3). The average
pCO2 could then be kept constant during the next 24
hours. The pH concomitantly increased by 0.12 (0.04 to
0.19) in the first 4 hours, remaining approximately con-
stant over the next 24 hours. No change was seen in ar-
terial bicarbonate concentrations, presumably due to
continuous dialysis against bicarbonate-containing di-
alysate. Despite an FiO2 of 1.0 in the gas flow to the gas-Table 3 Changes in systemic arterial pH, pCO2, bicarbonate (H
(t = 4 hours), and 24 hours (t = 24 hours) after starting low-flo
No. Art. pH A
t = 0 t = 4 hours ΔpH t = 0 t =
1 7.17 7.25 0.08 58
2 7.24 7.28 0.04 56
3 7.10 7.29 0.19 77
4 7.18 7.34 0.16 69
5 7.24 7.21a −0.03 88
6 7.07 7.18 0.11 77
7 7.37 7.44 0.07 55
8 7.16 7.24 0.09 66
9 7.18 7.31 0.13 79
10 7.18 7.37 0.19 65
Mean 7.18 7.30 0.12 69.00
Deltas indicate differences between t = 0 and t = 4 hours. Patient 5 was switched to
calculation of means and deltas at t = 4 hours. at = 2.5 hours.exchange device and a concomitant increase in the
extracorporeal pO2 in the first two patients, no change
occurred in their arterial pO2, which is consistent with
the dominant role of pulmonary gas exchange for arter-
ial pO2. The absence of a measurable effect on oxygen-
ation can most likely be attributed to the low blood flow
and thus to the low amount of oxygen provided for sys-
temic circulation. We therefore subsequently reduced
the FiO2 at the membrane oxygenator to 0.21 to avoid
potential side effects or counterregulatory vascular ef-
fects in the pulmonary circulation arising from possibly
increased oxygen tensions inside the pulmonary artery
and pulmonary capillary bed. Despite the improvements
in CO2 elimination, ventilator settings remained un-
changed or were slightly deescalated. In particular, at t =
24 hours, mean Pmax could be reduced from 32.50 to
28.67 mm Hg at t = 24 hours. Mean tidal volumes were
slightly decreased from 8.41 to 7.34 ml PBW, eventually
still not achieving 6 ml/kg PBW (Table 4).
Hemodynamic stability
In parallel to pH correction, a marked stabilization of
hemodynamics was observed (Figure 2). When the
hollow-fiber gas-exchanger CVVHD system was started,
nine of 10 patients received norepinephrine therapy, five
of these in doses between 0.6 and 5.0 mg/h (0.13 to 0.93
μg/kg/min). In four of these five patients with higher
doses, a marked hemodynamic stabilization with de-
creased norepinephrine doses (average 65% reduction)
could be achieved during the therapy (Table 5). In the
remaining hemodynamically unstable patient (number 1),
acidosis could not be corrected, and no hemodynamic
stabilization occurred. In terms of volume control,
patients were either ultrafiltrated because of volumeCO3) from the beginning (t = 0 hours), 4 hours
w CO2 removal
rt. pCO2 Art. HCO3
4 hours ΔpCO2 t = 0 t = 4 hours ΔHCO3
47 −11 20 20 0
51 −5 22 24 2
49 −28 23 23 0
52 −17 25 27 2
90a 2 37 34a −3
57 −20 20 19 −1
44 −11 31 30 −1
55 −11 23 23 0
55 −24 29 27 −2
36 −29 23 21 −2
49.56 −17.3 25.3 23.78 −0.22
ECMO after 2.5 hours of treatment and was therefore excluded from
Table 4 Ventilator settings from the beginning (t = 0 hours), 4 hours (t = 4 hours) and 24 hours (t = 24 hours) after starting low-flow CO2 removal
Number FiO2 (%) PEEP (mm Hg) Tidal volume (ml/pbw) Pmean (mm Hg) Pmax (mm Hg) Breathing rate
t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h
1 0.85 0.95 1.00 14 14 14 8.6 8.0 8.6 22 22 23 32 32 32 25 23 20
2 1.00 0.95 1.00 14 16 20 7.5 5.8 5.1 22 22 23 32 32 30 22 22 30
3 0.55 0.55 0.50 10 10 10 8.3 8.2 7.6 19 18 19 35 32 34 30 28 28
4 0.40 0.40 0.35 8 8 8 8.2 8.2 7.2 17 17 15 32 31 27 20 20 20
5 1.00 1.00a n.a. 13 13 a n.a. 8.6 6.5 a n.a. 23 23 a n.a. 40 40 a n.a. 20 24 a n.a.
6 1.00 0.95 0.60 12 12 12 9.0 8.8 8.0 20 19 19 34 33 31 20 20 20
7 0.37 0.37 0.37 12 12 10 9.6 9.5 8.1 16 14 13 27 23 21 12 12 14
8 0.50 0.50 0.50 15 15 15 9.8 8.4 6.7 21 21 21 33 33 30 20 20 26
9 0.80 0.70 0.60 12 12 14 7.9 9.6 7.7 19 19 18 28 28 25 28 28 24
10 0.40 0.40 0.50 12 12 12 6.6 8.6 7.1 19 19 18 32 32 28 26 26 26
Mean 0.69 0.64 0.60 12.20 12.33 12.78 8.41 8.34 7.34 19.80 19.00 18.78 32.50 30.67 28.67 22.30 22.11 23.11
n.a., not applicable. Patient 5 was switched to ECMO after 2.5 hours of treatment and was therefore excluded from calculation of means at t = 4 hours and












Figure 2 Clinical effects of low-flow CO2 removal 4 and 24 hours after commencement of treatment. Graphs illustrate mean changes of
values for pH (A), pCO2 (B), pO2 (C), tidal volume on respirator (D), norepinephrine dose at mg/h (E), and average changes in Pmax on the ventilator (F).
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tients, -645 to −3,345 ml/24 hours) or received volume
replacement as part of hypertensive shock therapy (six
patients, 180 to 2,945 ml/24 hours). No obvious differ-
ence was seen in the response to CO2 elimination be-
tween patients in whom either negative or positive
fluid balance was achieved. Exemplary time courses of
pH, pCO2, and norepinephrine dose in two patients
who were successfully treated with the low-flow RRT
system are shown in Figure 3.
Patients’ outcome
No serious adverse events could be attributed to the
hollow-fiber gas exchanger or the RRT circuit duringtreatment of the patients. Seven of 10 patients were suc-
cessfully weaned from the low-flow CO2 removal system,
improved their pulmonary function, and recovered from
critical illness (Table 1).
In the two patients (patients 1 and 2), who had contra-
indications for ECMO therapy, low-flow CO2 removal
was applied into the preexisting CVVHD devices as an
additional limited therapy option in very severe multiple
organ failure: both patients had H1N1 infection with pul-
monary ARDS and very low oxygenation indices (95/91).
Patient 1 had also a severe liver failure secondary to
preexisting alcoholic liver cirrhosis Child C. He died at
day 3 after study inclusion. Patient 2 had Hodgkin disease
and was undergoing chemotherapy. He had acquired
Table 5 Hemodynamic parameters from the beginning (t = 0 h), 4 hours (t = 4 h), and 24 hours (t = 24 h) after starting
low-flow CO2 removal
Number MAP (mm Hg) Heart rate Norepinephrine (mg/h) Norepinephrine (μg/kg/min) Lactate (mg/dl)
t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h t = 0 h t = 4 h t = 24 h
1 83 73 66 120 110 100 2.6 3.2 5.2 0.48 0.59 0.96 49 59 124
2 57 73 80 120 110 125 0.2 0.2 0.4 0.04 0.04 0.08 12 12 4.2
3 80 87 73 80 85 90 0.2 0.0 0.0 0.06 0.00 0.00 7 9 6
4 80 80 87 110 105 100 0.6 0.5 0.3 0.13 0.10 0.06 14 16 18
5 73 76a n.a. 110 100 a n.a. 0.2 0.3 a n.a. 0.04 0.06 a n.a. 11 9 a n.a.
6 70 77 93 110 90 90 5.0 2.0 1.0 0.93 0.37 0.18 43 47 12
7 70 73 90 70 65 95 0.1 0.0 0.0 0.02 0.00 0.00 6 7 9
8 66 63 73 110 90 90 1.2 1.2 0.9 0.17 0.17 0.13 12 13 14
9 80 82 73 105 110 110 0.0 0.0 0.0 0.00 0.00 0.00 7 7 8
10 73 87 93 100 85 80 1.9 0.9 0.0 0.32 0.15 0.00 10 12 9
Mean 73.20 77.22 80.89 103.50 94.44 97.78 n.a. n.a. n.a. 0.22 0.16 0.16 17.10 20.22 22.69
n.a., not applicable. Patient 5 was switched to ECMO after 2.5 hours of treatment and was therefore excluded from calculation of means at t = 4 hours and t = 24 hours.
at = 2.5 hours.
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We eventually limited intensive care support because of
the overall poor prognosis and in line with the patient’s
provision. He died at day 4 after commencing intensive
care therapy. Patient 5, with ARDS due to pneumonia,
was bridged to ECMO therapy for only 2.5 hours, before
ECMO cannulas were applied and an ECMO device was
available. He died 12 days later of multiorgan failure des-
pite continued ECMO therapy.
Discussion
For the first time we here report the use of a low-flow
hollow-fiber gas exchanger implemented in a CRRT cir-
cuit in a small series of critically ill patients. The simple
device proved to be efficient in terms of CO2 elimination,
was well tolerated, and did not lead to adverse events.
Concomitant renal-replacement therapy was in no way
compromised, and alarm functions of the CRRT system
ensured safety control for the gas-exchange device.
The concept of permissive hypercapnia has been de-
veloped to reduce baro- and volutrauma during ventila-
tion. Increased CO2 levels have been shown to be
associated with some potentially beneficial (for example,
antiinflammatory effects), but the resulting acidosis also
induces hemodynamic instability and potential cellular
adverse effects [4-7]. In our case series in eight of 10 pa-
tients, application of the gas-exchange filter led to a
rapid, partial, or complete correction of the pH and a
significant reduction of the pCO2 within 4 hours. Ranges
of CO2 reduction and pH correction were overall com-
parable to results obtained in the previous study of
Terragni et al. [24] using a standalone low-flow CO2-
removal system. In five of six hemodynamically unstable
patients requiring higher doses of norepinephrine(>0.5 mg/h/>0.1 μg/kg/min), pH correction was in line
with a marked reduction of vasopressor needs and an
improved hemodynamic stability. Norepinephrine doses
could be reduced to approximately one half after 6 to 8
hours on average; in three patients, vasopressors could
even be stopped. Hemodynamic stability correlated with
pH correction by enhanced CO2 elimination.
In the CRRT circuit used, blood flow was limited to
500 ml/min at maximum, provided that catheter flow
was optimal. We here used a high ratio of blood to gas
flow to achieve maximum CO2 elimination, although
lower blood/gas-flow ratios would be potentially effect-
ive as well. Achieved CO2 removal allowed correction of
acidosis, but we did not find a significant contribution to
the systemic oxygenation of the patients even when
higher FiO2 together with high gas/blood-flow ratios
were applied. Thus, additional systemic oxygenation can-
not be achieved with this low-flow device and is reserved
for extracorporeal lung replacement therapies with
higher flow rates, as in ECMO or PECLA therapy.
As it was a pilot, nonrandomized proof-of-concept
study, our study has several inherent limitations. First,
implementation of the device was one of multiple inter-
ventions in the severely ill patients under investigation.
Treatment included volume administration, antibiotic
treatment, and further co-medication to treat the under-
lying disease, which was sepsis in eight of 10 cases.
Treatment of acidosis was not confined to CO2 elimin-
ation by the respirator and the hollow-fiber gas exchan-
ger, but also included bicarbonate filtrate substitution
and proton dialysis during the course of renal-
replacement therapy. However, the time course of blood
pH and pCO2 in individual patients with immediate re-
sponses after the implementation of the hollow-fiber gas
Figure 3 Exemplary time courses for clinical effects of low-flow CO2 removal in two patients. Patient 10 had acute pneumonia (A, B, C);
patient 6 had cardiomyopathy and acute pneumonia (D, E, F) for pH, pCO2, and norepinephrine dose, respectively.
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Moreover, metabolic acidosis was already balanced by bi-
carbonate dialysis, when low-flow CO2 removal was
started, and bicarbonate levels remained more or less
stable during renal-replacement therapy and therefore
most likely did not contribute to the observed effects.
Second, we did not apply a standardized ventilation
protocol, which would have allowed testing for effects of
the intervention on ventilatory requirements or achiev-
ing low tidal volumes of 6 ml/kg PBW or less. However,
in our clinical setting, the hollow-fiber gas exchanger ina low-flow circuit CO2 at least compensated for respira-
tory acidosis and avoided further increases in ventilation
settings or even led to slight reductions of peak pressure
despite ongoing respiratory failure. Statistically, the over-
all survival in this small series was much higher than
predicted by the calculated APACHE II scores of the pa-
tients, but a sample size of 10 patients certainly does not
allow drawing any conclusions in respect to outcomes.
Despite this principal limitation of the hollow-fiber gas
exchanger inserted into an RRT circuit, the system may
have significant advantages in settings where the control
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when ECMO therapy is either still not indicated or simply
not available. The advantages of applying a hollow-fiber
gas exchanger in a CRRT circuit include its simplicity and
its potential applicability in nonspecialized centers, which
are experienced in renal-replacement therapy, as well as
the fact that no additional catheter placements are needed.
In contrast to many ECMO devices, available RRT ma-
chines are more secure and are equipped with distinct
alarm systems, which allow emergency shut-off due to air
or clots in the blood circuits. Regional anticoagulation
with citrate was not performed in conjunction with the
described setting, because of the necessity for increased
blood flows, but regional anticoagulation protocols could
possibly be developed, because a hemofilter allowing
clearance of calcium-citrate complexes is included in
the system, which is not the case in systems with isolated
hollow-fiber gas exchangers.
Conclusions
Implementation of a hollow-fiber gas exchanger in a low-
flow CRRT circuit was feasible and safe and let to a signifi-
cant CO2 removal and rapid correction of arterial pH in
critically ill patients with acute renal and respiratory failure,
with a positive impact on hemodynamic stability. Integra-
tion of a hollow-fiber gas exchanger could thus be poten-
tially an additive tool in the armamentarium of treatment
modalities in patients with multiorgan failure. To this
end, additional, larger, and controlled studies are certainly
needed to assess the impact of low-flow CO2 removal on
ventilator settings and patient prognosis.
Key messages
 Implementation of a hollow-fiber gas exchanger in a
low-flow CRRT circuit was feasible and safe
 Low-flow CO2 removal in a CRRT circuit
significantly removed CO2 and allowed rapid
correction of arterial pH in critically ill patients with
acute renal and respiratory failure
 Correction of arterial pH contributed to
hemodynamic stabilization of the patient
 Low-flow CO2 did not significantly contribute to
systemic oxygenation
 Low-flow CO2 removal complements but did not
substitute ECMO or PECLA therapy, when ECMO/
PECLA was indicated
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